Measurable or non-measurable disease per RECIST version (v).
Has measurable disease assessed by the investigator based on RECIST version ..
At least  measurable target lesion according to RECIST version .. CNS-only measurable disease as defined by RECIST version . is allowed.
Patient must have at least one measurable site of disease as defined by RECIST version (v)., determined by investigator review
Must have at least  site of measurable disease by RECIST criteria, by version .
Measurable disease per RECIST version (v)..
Presence of measurable disease as defined by RECIST version . Cohort : Patient Population: Relapsed/Refractory Ovarian Cancer
Presence of measurable disease as defined by RECIST version .
Measurable disease as per RECIST, version ..
Measurable disease per RECIST version (v).
Patients must have measurable disease as per RECIST (version .)
Patients must have measurable disease by RECIST criteria version .
For Part , cohorts -: evaluable disease (per RECIST version .). For Part , cohorts - and Parts  and : measurable disease (per RECIST version .)
Have measurable disease per RECIST version ..
Have measurable disease, as defined by RECIST version .;
Measurable disease per RECIST version ..
Has measurable disease based on RECIST version.
Have measurable disease per RECIST version (v).
Participants must have at least  lesions with measurable disease as defined by RECIST Version .
Participants must have measurable disease by RECIST version .
Measurable disease as defined by RECIST criteria (version .)
Measurable target tumors using standard imaging techniques (RECIST version [v.] . criteria)
Patients must have disease that is measurable by RECIST version .
Measurable disease as defined by RECIST version . by radiologic methods on or after the most recent line of therapy. For Cohort , imaging must be available for central review.
Measurable disease (revised RECIST; Version .)
Measurable disease (revised RECIST; Version .)
For Part , measurable disease as defined by RECIST, Version . including bone-only disease
For dose-escalation cohort, patient has at least  measurable disease as defined by RECIST criteria (Version .). For dose-expansion cohort, patient has at least  measurable disease as defined by RECIST criteria (version .) with a lesion larger than . cm that can be biopsied by core needle biopsy.
COHORT EXPANSION PHASE: Patient must have measurable lesions as defined by RECIST version . criteria
Measurable disease as defined by RECIST version .
Measurable disease, as defined by RECIST Version . (v.).
Subjects must have measurable disease as defined per RECIST Version ..
Measurable disease defined by RECIST version ., or bone-only disease
Measurable disease in accordance with RECIST version .
Patient has measurable disease, as determined by the Investigator using RECIST, version ., as determined within  days before baseline (CD).
Measurable disease, as defined by RECIST version .
PART B: Patients must have measurable disease as per RECIST version .
Have evidence of measurable disease as defined by RECIST Version .
Measurable disease by RECIST version .
Measurable disease by RECIST version ..
Tumors must have measurable disease as per RECIST (version .);
Patient must have measurable lesions as defined by RECIST version . criteria
Patients must have measurable disease per RECIST criteria version (v.) .
Measurable disease as per RECIST Version . criteria.
Measurable disease using RECIST criteria (version .).
Measurable disease at baseline in accordance with RECIST Version .
Measurable disease as per RECIST guideline (Version .);
Measurable disease at baseline as per RECIST version .
Have measurable disease based on RECIST version (v) . for solid tumors
Subjects must have measurable disease by RECIST Version ..
Histologically confirmed, metastatic TNBC with measurable disease per RECIST version ..
Measurable disease per RECIST version ..